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S U M M A R Y
Objective: To describe and compare the characteristics of children hospitalized with novel inﬂuenza A
(H1N1) during two successive waves.
Methods: This was a medical chart review of all children hospitalized in a French Canadian pediatric
hospital inMontreal in the spring and fall of 2009with a positive real-time polymerase chain reaction for
novel inﬂuenza A (H1N1) and ﬂu-like symptoms.
Results: We included 202 children with a median age of 4.9 (range 0.1–18) years. Demographic and
clinical features of the children in the two waves were similar. One or more underlying medical
conditions were found in 59% of the children. Clinical ﬁndings at admission were: fever (98%), cough
(88%), congestion/rhinorrhea (58%), gastrointestinal symptoms (47%), oxygen saturation below 95%
(33%), sore throat (20%), and neurological symptoms (9%). Admission to the intensive care unit was
required for 22 (11%) children, and 14 patients needed respiratory support. During the second wave, the
median duration of staywas shorter (3 vs. 4 days, p = 0.003) and oseltamivir was usedmore often (84% vs.
40%, p < 0.001).
Conclusions: Children hospitalized during the two successivewaves of H1N1weremainly school-aged and
suffered frommoderate disease. Although clinical features and severity of diseasewere similar, oseltamivir
was prescribed more frequently and the length of hospital stay was shorter in the second wave.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In April 2009, the ﬁrst cases of novel inﬂuenza A (H1N1) were
observed in Mexico and the southern USA.1 The virus then quickly
spread worldwide, demonstrating efﬁcient human-to-human
transmission. On June 11, 2009, the World Health Organization
(WHO) ofﬁcially raised the pandemic alert to phase 6. Currently
available data indicate that most infections with the novel
inﬂuenza A (H1N1) have resulted in self-limited, uncomplicated
disease.2,3,4,5,6,7 Nevertheless, there have been many observations
of severe respiratory diseases and deaths among young and
previously healthy people, particularly pregnant wom-
en.8,9,10,11,12,13,14 In terms of incidence of this new inﬂuenza,
children appear to be the most affected population.5 Data* Corresponding author: Tel.: +514 345 4931x5566; fax: +514 345 4908.
E-mail address: bruce_tapiero@ssss.gouv.qc.ca (B. Tapie´ro).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.08.006regarding the most severely ill children suggest that most of
them had preexisting co-morbidities.12,15
In Montreal, Canada, the ﬁrst case of novel inﬂuenza A (H1N1)
was diagnosed on April 24, and the virus spread very quickly. In
the province of Quebec, there were 2812 laboratory-conﬁrmed
cases during the ﬁrst wave in the spring of 2009 and 11 361
laboratory-conﬁrmed cases during the second wave in the fall of
2009.16,17
According to historical reports on the 1918–1919 pandemic ﬂu,
increasing severity throughout successive waves of infection is a
possibility.18We did not knowwhether the population targeted by
the virus during the ﬁrst wave would be the same as that during
the second wave, or whether co-infection with other respiratory
viruses would lead to more severe diseases.19 During the ﬁrst
wave, several cases of viral oseltamivir resistance mutations were
reported.20 The occurrence of such resistance could have led to a
less optimal control of the disease. Directly confronted with this
emerging infection, we wanted ﬁrstly to describe this new disease
in hospitalized children and secondly to assess if clinical featuresses. Published by Elsevier Ltd. All rights reserved.
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ogy and disease severity.
2. Methods
2.1. Study population and design
Sainte-Justine Hospital is the largest pediatric tertiary-care
hospital in the province of Quebec, Canada (500 beds), with 20 000
hospital admissions and 60 000 emergency room visits each year.
Although it is a tertiary-care hospital with province-wide scope, it
also delivers primary pediatric care to children on the Island of
Montreal and surrounding areas (around 440 000 children).
Between April 28 and July 15, 2009, all children admitted with
ﬂu-like symptoms were tested for the novel inﬂuenza (H1N1)
virus, and then according to the WHO recommendations for ﬂu
surveillance, testing was resumed on August 30.
Using the hospital virology laboratory database to identify
patients, we retrospectively reviewed the medical charts of all
children (age 0–18 years) admitted with laboratory-conﬁrmed
inﬂuenza A (H1N1) between April 28 and July 15 (ﬁrst wave) and
between August 30 and December 15 (second wave). Data were
collected by two of the authors (LC and EL) using a structured
collection form. After chart review, hospitalizations not related to
inﬂuenza were excluded. As is largely accepted in the literature, a
ﬂu-like illness developing 72 h or more after hospital admission
was considered as nosocomially acquired.21 For the purpose of our
study, i.e., hospitalizations related to H1N1, we elected to study
only those children with a nosocomial H1N1 infection leading to
prolonged hospitalization. Data collected included age, gender,
presence of chronic medical conditions, date and nature of the ﬁrst
symptoms, and date of the ﬁrst medical consultation, as well as
delay between onset of the disease and the ﬁrst consultation.
Reason for admission, initial physical examination ﬁndings,
admission diagnosis, clinical evolution, treatments (antiviral,
antibiotics, oxygen therapy, continuous positive airway pressure
(CPAP), and mechanical ventilation), and radiological examination
results at admission and during hospitalization were recorded.
Admission to the intensive care unit (ICU), outcome, and duration
of stay, as well as culture results from blood, cerebrospinal ﬂuid
(CSF), and other sites for bacteria or viruses were also noted.
2.2. Study deﬁnitions
According to theWHO clinical deﬁnition, an inﬂuenza infection
is an acute febrile respiratory illness with inﬂuenza-like symptoms
including fever, cough, headache,muscle and joint pain, sore throat
and runny nose, vomiting and diarrhea.22 Atypical but previously
described features like encephalopathy, febrile seizures, rhabdo-
myolysis with renal failure, myocarditis, and toxic shock were also
considered as related to inﬂuenza if no other obvious etiology was
found.23,24 Respiratory symptoms were deﬁned as cough, rhinor-
rhea/congestion, shortness of breath, or sore throat. Gastrointesti-
nal symptoms were deﬁned as vomiting, abdominal pain, or
diarrhea. Fever was deﬁned by a rectal temperature above 38 8C or
an axillary or oral temperature above 37.5 8C.
Objective dyspnea was considered present if the terms
difﬁculty breathing, intercostal retraction, nasal ﬂaring, respirato-
ry distress, or dyspnea were mentioned in the medical notes.
Hypoxemia was deﬁned as an oxygen saturation below 95% by
pulse oximetry in room air. Tachypnea, tachycardia, and hypoten-
sion were deﬁned for all age categories according to the
international conference of consensus on sepsis in children.25
The deﬁnition of inﬂuenza-related encephalopathy was the one
used by the US Centers for Disease Control and Prevention (CDC):
‘‘a person aged<18 years with alteredmental status or personalitychange lasting >24 hours and occurring within 5 days of onset of
an acute febrile respiratory illness’’ plus ‘‘laboratory or rapid
diagnostic test evidence of acute inﬂuenza virus infection
associated with the respiratory illness’’.26
Pediatric radiologists interpreted all X-rays at the time of
admission. Pneumonia was deﬁned as the presence of an alveolar
consolidation on chest X-ray.
2.3. Virology
The virus was detected in nasopharyngeal aspirates or throat
swabs, as recommended by the WHO,27 using two separate real-
time polymerase chain reaction (RT-PCR) assays, one for the
detection of the inﬂuenza A virus, the other speciﬁcally for the
novel inﬂuenza A (H1N1). The conventional and real-time reverse
transcriptase PCR (rRT-PCR) methods used were carried out
according to the protocols provided by the National Microbiology
Laboratory of Canada and the CDC, or developed in-house at the
Laboratoire de Sante´ Publique du Que´bec, the provincial microbi-
ology reference laboratory.
2.4. Statistical analysis
Continuous variables were compared using the Student’s t-test
or the Wilcoxon rank-sum test. Categorical variables were
analyzed using the Chi-square test. A regression model was used
to assess the effect of covariates on length of stay. Hazard ratios
(HRs) were estimated using a Cox proportional hazard model.
Exploratory analyses stratiﬁed on the wave and the administration
of antiviral treatment were done to test the inﬂuence of the
treatment in each wave and to test the inﬂuence of the waves for
the subgroups who did or did not receive antivirals. These factors
were adjusted for all the other covariates in the model.
Data were analyzed using SAS software, version 9.2 (SAS
Institute, Cary, NC, USA). A p-value of <0.05 was regarded as
statistically signiﬁcant.
The study was approved by the institutional review board of
Sainte-Justine Hospital.
3. Results
3.1. Patient characteristics
Among the 1995 children tested for novel inﬂuenza A (H1N1),
622 were positive. Of these, 222 children were hospitalized; 11
were excluded from the analysis because their hospital admission
was not directly related to inﬂuenza. Data from 202 children were
included in the analysis (Figure 1). A nosocomial inﬂuenza
infection was diagnosed in the other nine patients (two in the ﬁrst
wave and seven in the secondwave); these patients were analyzed
separately.
During the ﬁrst wave (78 cases), the ﬁrst hospitalized patient
was admitted on May 17 and the last on July 1, whereas the ﬁrst
admission for H1N1 during the second wave (124 cases) occurred
on October 18 and the last one on December 4. There were no
differences in the characteristics of the patients in the two waves,
as shown in Table 1. Themedian age of patientswas 4.9 (range 0.1–
18) years and the male/female sex ratio was 1.02. One or more
chronic medical conditions were found in 120 children (59%).
Among these children, 60 (50%) had respiratory involvement, with
asthma being the most frequent (n = 46, 38%). Among children
without respiratory conditions, immunosuppression (n = 14, 12%)
and sickle cell disease (n = 11, 9%) were the most frequent
underlying medical conditions. Encephalopathy (n = 12) was most
often associated with chronic respiratory conditions (recurrent
aspiration (n = 4) or asthma (n = 4)). Themedian delay between the
[(Figure_1)TD$FIG]
1995 children tested by RT-PCR for 
novel influenza A (H1N1) 
400 outpatients 
222 hospitalizations
11 hospitalizations not directly related to 
influenza:
6 systematic screening without flu 
symptoms (3 polytrauma, 1 post-
surgery, 1 transient synovitis) 
2 elective hospitalizations with 
minor symptoms without 
prolongation of hospitalization 
3 hospitalizations for another 
obvious reason with minor 
symptoms without prolongation of 
hospitalization (appendicitis, toxic 
hepatitis, severe hypocalcemia) 
9 nosocomial infections  
202 children hospitalized for 
novel influenza A (H1N1) 
622 children with a 
positive RT-PCR 
Figure 1. Flowchart showing the children included in chart review.
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days. Thirty-ﬁve (28%) children hospitalized during the second
wave had received the adjuvanted monovalent vaccine against
H1N1. The median delay between vaccination and the occurrence
of the ﬁrst symptoms was 3 (range 2 to 18) days. Three children
developed inﬂuenza 10 days or more after the vaccination, two of
them were immunosuppressed.
3.2. Clinical features
Reasons for consultation were isolated fever (n = 21, 10%), fever
with respiratory symptoms (n = 143, 71%), febrile seizures (n = 14,
7%), fever and gastrointestinal symptoms (n = 13, 6%), fever and
neurological disorders other than seizure (lethargy or confusion;
n = 4, 2%), and others (n = 7, 3%). These were not different between
the two waves. On admission, 47% of the children had at least one
gastrointestinal symptom and 9% had neurological anomalies
(Table 2). Clinical, radiological, and biological ﬁndings at admission
are shown in Table 2; these were also similar between the two
waves. Initial physical examination revealed abnormal ausculta-Table 1
Demographic features of the 202 hospitalized children
First wave
(n=78)
Median age, years (min–max) 5.9 (0.1–18)
Age, n (%)
0–6 months 8 (10)
6–24 months 9 (11)
24 months–5 years 16 (21)
>5 years 45 (58)
Sex ratio (M/F) 1
Presence of any underlying medical disease, n (%) 50 (64)
Delay between ﬁrst symptoms and ﬁrst medical
consultation, days (min–max)
2 (0–10)tion for 81 children (40%), objective dyspnea in 64 cases (32%), and
hypoxemia below 95% in 66 children (33%), of whom 20 (30%) had
severe hypoxemia below 90% (Table 2). Chest X-rays were done on
admission for 192 patients; 120 (63%) were interpreted as
abnormal by a pediatric radiologist (Table 2).
3.3. Microbiology
Among the blood cultures drawn in 154 children, one was
positive for Streptococcus pneumoniae. Lumbar puncture done in 17
children did not show biological evidence of meningitis, and CSF
bacterial and viral cultures were all negative. Following nasopha-
ryngeal aspiration, respiratory syncytial virus (RSV) co-infection
was documented in four children. Throat cultures were positive for
group A Streptococcus in four cases (toxic shock syndrome, scarlet
fever rash, pharyngitis, and no clinical signs of superinfection).
Expectorations from two children without previous underlying
respiratory diseases and a pneumonia documented on X-ray
yielded Staphylococcus aureus for one and Streptococcus pyogenes
for the other. Positive endotracheal cultures for S. pneumoniae (1)Second wave
(n=124)
Whole cohort
(n=202)
Comparison
p-value
4.2 (0.1–18) 4.9 (0.1–18) 0.24
12 (10) 20 (10) 0.89
17 (14) 26 (13) 0.65
41 (33) 57 (28) 0.05
54 (43) 99 (49) 0.05
1.03 1.02
70 (56) 120 (59) 0.25
1 (0–8) 1.5 (0–10) 0.13
Table 3
Medical interventions
Duration of hospitalization, days (min–max)
Admission in ICU, n (%)
Length of stay in ICU, days (min–max)
Antiviral, n (%)
Delay between ﬁrst symptoms and antiviral administration, days (min–max)
Antibiotherapy, n (%)
Median duration of antibiotherapy, days (min–max)
Oxygen therapy, n (%)
Duration of oxygen therapy, days (min–max)
B2 mimetic, n (%)
Steroids oral, n (%)
Steroids IV, n (%)
Drain pleura, n (%)
ICU, intensive care unit; IV, intravenous.
Table 2
Symptoms and clinical, radiological, and biological ﬁndings at admission
First
wave
Second
wave
Whole
cohort
Symptoms n=78 n=124 n=202
Fever 77 (99) 118 (95) 197 (98)
Cough 66 (85) 111 (90) 177 (88)
Congestion/rhinorrhea 48 (62) 69 (56) 117 (58)
Gastrointestinal symptoms 39 (50) 56 (45) 95 (47)
Abdominal pain 9 (12) 19 (15) 28 (14)
Vomiting 31 (40) 47 (38) 78 (39)
Diarrhea 11 (14) 12 (10) 23 (11)
Decreased intake 33 (42) 44 (35) 77 (38)
Sore throat/odynophagia 23 (29) 18 (14) 41 (20)
Dyspnea 22 (28) 45 (36) 67 (33)
Headaches 16 (21) 23 (19) 39 (19)
Rash 9 (12) 6 (5) 15 (7)
Non-purpuric 5 (6) 2 (2) 7 (3)
Purpuric 4 (5) 4 (3) 8 (4)
Chills 7 (9) 6 (5) 13 (6)
Neurological anomalies 11 (14) 8 (6) 19 (9)
Seizures 7 (9) 8 (6) 15 (7)
Lethargy 3 (4) 0 3 (1.5)
Confusion 1 (1) 0 1 (0.5)
Clinical ﬁndings n=78 n=124 n=202
Tachypnea 46 (59) 99 (80) 145 (72)
Oxygen saturation <95% 28 (36) 38 (31) 66 (33)
Oxygen saturation <90% 9 (12) 11 (9) 20 (10)
Hypotension 4 (5) 6 (5) 10 (5)
Abnormal lung auscultation 30 (38) 51 (41) 81 (40)
Effort of breathing 25 (32) 39 (31) 64 (32)
Pharyngitis 15 (19) 17 (14) 32 (16)
Conjunctivitis 4 (5) 9 (7) 13 (6)
Otitis 3 (4) 13 (10) 16 (8)
Radiological ﬁndings n=74 n=118 n=192
Normal 29 (39) 43 (36) 72 (38)
Alveolar condensation 26 (35) 45 (38) 71 (37)
Pleural effusion 4 (5) 8 (7) 12 (6)
Interstitial inﬁltrate 5 (7) 3 (3) 8 (4)
Bronchovascular network 8 (11) 16 (14) 24 (13)
Pneumothorax +
pneumomediastinum
1 (1) 2 (2) 3 (2)
Cardiomegaly 1 (1) 1 (1) 2 (1)
Hemogram n=78 n=117 n=195
Lymphopenia <1109/la 14 (18) 16 (14) 30 (15)
Thrombocytopenia <150109/la 12 (15) 4 (3) 16 (8)
Results are n (%). The proportions are expressed with a denominator of the number
of children hospitalized with inﬂuenza A (H1N1) for whom data were available. All
the children had data available for symptoms and clinical examination (n=202); no
X-ray was done for 10 children (n=192) and no hemogram was done for seven
children (n=195).
a Children with hematological diseases or myelosuppressive therapy were
excluded.
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cultures of intubated children. One child with pleural empyema
had a positive PCR S. pneumoniae in the pleural ﬂuid.
3.4. Treatment
Antibiotic therapy was initiated at admission for 152 children
(75%); 61 (30%) received intravenous (IV) ceftriaxone or cefotax-
ime, 51 (25%) IV ampicillin, 22 (11%) other IV antibiotics, and 18
(9%) oral macrolide as monotherapy. Antibiotic treatment was
prescribed for a total median duration of 9 (range 0–44) days and
was discontinued before 72 h for 43 patients (28%). Oxygen
therapy was needed for 51 patients (25%) for a median duration of
2 (range 1–16) days (Table 3). Aggressive intravenous ﬂuid
rehydration because of tachycardia or hypotension was adminis-
tered in 21 (10%) children. The use of antiviral medication was
statistically different between the two waves: 31 children (40%)
received oseltamivir during the ﬁrst wave versus 104 (84%) in the
second wave (p < 0.001) (Table 3).
3.5. Clinical evolution
Nineteen children had a clinical or radiological respiratory
worsening with the occurrence after admission of alveolar
condensation (n = 8), pleural effusion (n = 6), progressing pleural
effusion (n = 4), and pneumothorax (n = 1). Pulmonary bacterial
superinfection was clinically suspected in 83 (41%) children, but
documented from blood, endotracheal, or expectoration cultures in
only eight cases. The diagnoses on dischargewere pneumonia for 74
children (37%), uncomplicated inﬂuenza infection for 55 (27%),
asthma exacerbation for 17 (8%), deterioration of an underlying
medical condition for 11 (5%), atypical febrile seizures for 10 (5%),
acutegastroenteritisordehydrationforseven(3%), inﬂuenza-related
encephalopathy for three (2%), acute respiratory distress syndrome
(ARDS) for three (2%), bronchiolitis for three (2%), andmiscellaneous
for 19 (9%), including two cases of toxic shock syndrome.
3.6. Intensive care hospitalization
ICU admission was required for 22 children (11%; 13 directly
from the emergency room and nine transferred from the wards).
One or more chronic medical conditions were found in 14 of these
children (64%), which was not different from those patients not
requiring ICU admission. Information on ICU stay is given in Table
4. The median duration of stay in the ICU was 3 (range 1–32) days.
A 10-year-old girl, admitted for an H1N1-related acute respiratory
disease, deteriorated because of digestive bleeding from an
esophageal–tracheal ﬁstula and subsequently died.First wave
(n=78)
Second wave
(n=124)
Whole cohort
(n=202)
Comparison
p-value
4 (0–28) 3 (1–21) 3 (0–28) 0.003
12 (15) 10 (8) 22 (11) 0.10
2 (1–12) 4 (1–32) 3 (1–32) 0.14
31 (40) 104 (84) 134 (66) <0.001
3 (0–13) 2 (0–10) 2 (0–13) 0.42
63 (81) 89 (72) 152 (75) 0.15
9.5 (1–30) 8 (0–44) 9 (0–44) 0.15
21 (27) 30 (24) 51 (25) 0.66
2 (1–16) 2 (1–9) 2 (1–16) 0.05
17 (22) 42 (34) 59 (29) 0.07
9 (12) 15 (12) 24 (12) 0.9
2 (3) 13 (10) 15 (7) 0.04
2 (3) 5 (4) 7 (3) 0.45
Table 4
Characteristics cause of admission, treatment, and outcomes of the 22 children admitted to the ICU
Age
(years)
Underlying conditions Delay between
hospitalization
and transfer to
the ICU (days)a
Cause of
admission to ICU
Mechanical
ventilation
(duration
in days)
CPAP
(duration
in days)
Catecholamines
(duration in
days)
Outcome Duration
of stay
Final diagnosis
14.4 None 0 Hemodynamic
failure
(hypotension)
No No No Alive, discharged 1 Toxic shock syndrome
with inﬂuenza and group
A Streptococcus in throat
culture
13.7 Hemoglobinopathy C/C 0 Confusion, suspicion
of encephalitis
No No No Alive, discharged 1 No proof of encephalitis,
confusion related to viral
infection and fever
10.9 VACTER syndrome,
prematurity, chronic
lung disease, asthma,
encephalopathy
4 Digestive bleeding
and respiratory
distress
Yes No Yes (6) Dead 5 Respiratory distress and
digestive bleeding with
esophageal–tracheal ﬁstula
with inﬂuenza infection
6.5 None 0 Respiratory distress Yes (1) No No Alive, discharged 2 Pneumothorax related to
inﬂuenza infection (without
lung malformation
or anatomic predisposition)
0.1 Prematurity 32 weeks 7 Respiratory distress
with acute life-
threatening event
Yes (5) Yes (4)b No Alive, discharged 12 Acute life-threatening event
related to viral infection
(mechanical obstruction)
5.3 Encephalopathy with
recurrent aspiration
pneumonia
3 Digestive bleeding No No No Alive, discharged 1 Digestive bleeding related
to mechanical irritation
(gastrostomy),
superinfection with
bacterial pneumonia
5.5 Sickle cell disease 2 Respiratory distress No Yes (2) No Alive, discharged 3 Acute chest syndrome with
inﬂuenza infection
17.2 None 0 Hemodynamic
failure
(hypotension)
No No Yes (1) Alive, discharged 2 Toxic shock syndrome
without any bacterial
documentation
nor focal infection
0.4 Tetralogy of Fallot 0 Cardiac failure Yes (1) No No Alive, discharged 6 Cardiac failure consecutive
to viral infection
13.4 Encephalopathy with
recurrent aspiration
pneumonia and chronic
respiratory insufﬁciency
2 Respiratory distress No Yes (1) No Alive, discharged
and rehospitalized
with respiratory
distress
4 Complicated inﬂuenza
infection with
bacterial pulmonary
superinfection and
respiratory distress
0.5 Epilepsy and development
retardation
0 Uncontrolled seizures No No No Alive, discharged 1 Seizure consecutive to
fever in viral context
and predisposition
3.2 None 0 Hemodynamic failure
(hypotension)
No No No Alive, discharged 2 Unexplained hypotension
with hypoalbuminemia,
suspicion of capillary
leak syndrome
14.2 Tetralogy of Fallot,
common variable
immunodeﬁciency and
asthma
0 Respiratory distress No Yes (2) No Alive, discharged 3 Pneumonia with
respiratory failure
16.9 Acute leukemia with bone
marrow transplant, chronic
GVHD, invasive pulmonary
aspergillosis with lobectomy
10 Respiratory distress Yes (12) Yesb (14) Yes (4) Alive, hospitalized 30 ARDS
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Table 5
Cox proportional hazard model
HR 95% CI p-Value
Gender (male) 1.02 0.75; 1.38 0.91
Age >5 yearsa 1.06 0.71; 1.58 0.77
Age 24 months–5 yearsa 0.82 0.52; 1.30 0.39
Delay between the occurrence
of the ﬁrst symptoms and
the hospitalization (>2 days)
1.23 0.89; 1.71 0.21
Tachypnea 1.02 0.66; 1.57 0.93
Effort of breathing 1.20 0.77; 1.89 0.42
Presence of any chronic
underlying medical condition
0.86 0.58; 1.28 0.46
Presence of respiratory
underlying disease
1.09 0.71; 1.68 0.70
Any abnormal ﬁnding on
chest X-ray
1.41 0.94; 2.11 0.10
Unifocal or multifocal alveolar
condensation on chest X-ray
1.09 0.68; 1.74 0.73
Administration of antiviral
(oseltamivir)
1.64 1.12; 2.39 0.011
Admission to the ICU 2.04 1.04; 4.03 0.04
Hospitalization during the
ﬁrst wave
1.72 1.18; 2.53 0.005
Effect of antiviral stratiﬁed
by waveb
First wave 2.51 1.22; 5.13 0.014
Second wave 1.34 0.75; 2.41 0.32
Effect of waves stratiﬁed by
antiviral treatmentb
No antiviral treatment 1.17 0.55; 2.45 0.69
Antiviral treatment 1.91 1.14; 3.18 0.014
HR, hazard ratio; CI, conﬁdence interval; ICU, intensive care unit.
a Age under 22 years was the reference age group (HR=1).
b Adjusted for all other covariates.
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The median duration of hospitalization during the second wave
was signiﬁcantly shorter than during the ﬁrst wave: 3 (range 1–21)
days vs. 4 (range 0–28) days, respectively (p = 0.003). The median
duration of hospitalization for thewhole cohortwas 3 (range 0–28)
days. One patient died during the hospital stay and three patients
were hospitalized for longer than 28 days. All these patients were
censored for the regression model.
In multivariate analysis, the risk factors for being hospitalized
more than 3 days were ICU admission (HR 2.04; 95% conﬁdence
interval (CI) 1.04–4.03), prescription of antiviral (HR 1.64; 95% CI
1.12; 2.39), and hospitalization during the ﬁrst wave (HR 1.72; 95%
CI 1.18; 2.53) (Table 5). After a stratiﬁcation by wave, the inﬂuence
of the administration of antiviral treatment remained only for the
ﬁrst wave.
3.8. Nosocomial infections
Nine children had a hospital-acquired H1N1 infection that
prolonged their hospital stay. Themedian time between admission
and the occurrence of ﬂu symptoms was 15 (range 4–112) days.
During the ﬁrst wave, a 9-month-old girl hospitalized for an RSV
bronchiolitis complicating congenital heart disease had a further
respiratory degradation with a newly documented inﬂuenza
infection, and a 13-year-old boy hospitalized for acute appendicitis
developed an inﬂuenza-like illness on the fourth day of hospitali-
zation. During the second wave, three premature babies were
infected; two of them were also co-infected with RSV and needed
to be reintubated. Two children hospitalized in the hematology/
oncology unit for chemotherapy and two others hospitalized for
elective surgery were infected nosocomially. All of these children
received oseltamivir. One of the premature infants died more than
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considered as related to H1N1.
4. Discussion
We have described the clinical features of the largest cohort of
hospitalized children for novel inﬂuenza A (H1N1) during the two
successive waves in Canada. We found that hospitalized children
were generally school-aged, with amedian age around 5 years, and
59% of them had underlying medical conditions recognized to be
risk factors for complicated seasonal inﬂuenza and therefore
needed to be immunized as a priority. The remaining 41%were not
considered as high-risk and were supposed to be vaccinated later
in time. In fact, in Canada, the vaccine only became available after
the beginning of the second wave, and most of the children were
not protected through adequate immunization given in a timely
manner. We also noted that ICU admission was required for 11% of
cases. The demographic and clinical features of the children were
similar between the two waves, but the use of oseltamivir and the
length of hospitalization were different.
Our ﬁndings are globally consistent with the preliminary
reports of novel inﬂuenza A in pediatric patients, particularly
concerning the proportion of underlying medical conditions and
the median age of patients.4,5,6,7,8,12,28,29 This last point could be
linked to the fact that school played an important role in spreading
the disease at the initial stages in several countries.30,31,32,33 In
Quebec, government-subsidized daycare for children is very
common, and starts at 1 year of age. Consequently the majority
of children enter the community early in life and hence could be
major transmitters of the infection. Despite this fact, children
younger than 5 years were neither the most frequent age range
hospitalized nor the most critically ill in our experience. This is at
odds with what is described for seasonal inﬂuenza, where children
under the age of 2 years are more severely affected.7,24,34,35,36 The
high frequency of patients with underlying conditions (59%)
among hospitalized children has also been noted in other reports
about novel inﬂuenza A (H1N1) in adults29,37,38 and with seasonal
inﬂuenza among children;35,36 this reinforces the need to prioritize
early immunization programs and antiviral therapy in this group.
We also found a high frequency (47%) of digestive symptoms,
known to be more frequent among children than adults for
seasonal inﬂuenza39 and more common for inﬂuenza B infection
among children.40 Some inﬂuenza H1N1-infected children pre-
sented with gastroenteritis without respiratory symptoms and
were hospitalized for dehydration, therefore clinicians should keep
in mind that respiratory isolation methods should be applied for
patients with gastrointestinal symptoms in the setting of inﬂuenza
outbreaks.
Neurological features were also common (9%); most of them
were febrile seizures. Three children were diagnosed with
inﬂuenza-related encephalopathy according to the CDC deﬁni-
tion.26 Inﬂuenza-related febrile convulsions have been reported at
a rate of 40% with seasonal inﬂuenza.41 However, the majority of
the children in this cohort were under the age of 3 years, consistent
with the usual age-speciﬁc pattern of febrile seizures. In 2007,
Newland et al. published a report on neurological complications
among hospitalized children with inﬂuenza: 72 of 842 patients
(8.5%) had neurological complications; among them 40 had no
previous neurological or neuromuscular disease.23 Neurological
complications were also recently described in four children
infected by novel inﬂuenza A (H1N1) in Dallas.42
Pneumonia was the most frequent complication of inﬂuenza,
which represented more than one third of the diagnoses leading to
hospitalization (37%); the majority of the antibiotics were
prescribed in these patients. However, bacterial superinfection
with S. pneumoniae was documented with certainty in only twocases with positive blood culture or positive PCR in pleural ﬂuid.
Invasive pneumococcal disease is known to have an increased
incidence after viral infection.43 Two children fulﬁlled the
diagnostic criteria of staphylococcal or streptococcal toxic shock
syndrome.44 Neither had a documented bacterial focus of
infection, but group A Streptococcus was found in the throat
culture of one of the cases. Toxic shock, particularly due to S.
aureus, is awell recognized entity in pediatric inﬂuenza infection.45
As this complication is one of the most serious of inﬂuenza,
physicians must bear it in mind in the context of pandemic
inﬂuenza.
It is well known that antibiotics are overused in the setting of
viral infection in children.46 In our series, antibiotics were started
for 75% of the patients; this high proportion could be explained in
part by the fact that almost 50% of the patients had a chest X-ray
compatible with bacterial infection and that 59% had underlying
medical conditions. This high proportion is comparable with that
described by Quach et al. in a description of seasonal inﬂuenza
(69% of the children received IV antibiotics upon admission) and by
Libster et al. in a description of pandemic H1N1 2009 in Argentina
(74% received antibiotics).11,24
The children hospitalized during the two waves were not
different in their demographic or clinical features, but their
management was different. Firstly, information about the novel
inﬂuenza H1N1 was abundant during the second wave; this
certainly inﬂuenced physician decisions regarding diagnosis and
treatment. Secondly, the availability of oseltamivir was greater
during the second wave and more information regarding infant
dosing was available. The duration of hospitalization was
signiﬁcantly shorter (1 day) in the second wave; this difference
could not be explained by the characteristics of the population or
the severity of the disease because these features were the same
between the two waves. We did not ﬁnd any evidence that the
more liberal prescription of oseltamivir was related to shorter
duration of hospitalization. On the contrary, during the ﬁrst wave
we showed a link between the prescription of oseltamivir and a
longer duration of hospitalization. It seems that during the ﬁrst
wave the prescription of oseltamivir was reserved for the most
severe patients who consequently had a longer duration of
hospitalization. Our hypothesis is that the clinical experience
acquired by physicians during the ﬁrst wave, as well as pressure
from the family in the setting of media-generated anxiety,
inﬂuenced the clinical decisions of the physicians when patients
of the second wave sought medical attention for inﬂuenza-like
illnesses. More oseltamivir was prescribed and patients were
discharged earlier, as doctors realized the illness was less severe
than had been originally feared.
In Quebec the ofﬁcial vaccination campaign started on October
26 – week 44 – whereas the peak of the second wave occurred
during week 45.17 In February 2010, the vaccination coverage in
Quebec was estimated at 57.3% for the general population and at
78% for children aged between 6months and 5 years. However, the
vaccination campaign was very gradual and at the time of the
second wave peak the vaccination coverage was less than 10%.47
Among the children hospitalized during the second wave, 70 had
an underlying disease and were thus eligible for prioritized
vaccination; nevertheless only 35 were vaccinated at the time of
admission and among these, only three had enough time to
develop protective immunity. The vaccination campaign started
too late to protect these children, but it is difﬁcult to predict how
that second wave would have evolved without the mass
vaccination program.
Nosocomial infections were also an important issue during the
two waves. Nine children were infected during their hospital stay,
among whom two were premature babies who were seriously ill
and reintubated. Avoiding nosocomial infections is a necessity,48
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from the infection control division in terms of visitor triage,
education, immunization, andmanagement of healthcare workers.
The need to isolate and cohort patients also created problems with
the regular functioning of the hospital wards.
Our study has several limitations. The retrospective nature of
this cohort study might have led to omissions or misclassiﬁcations
of information; nevertheless, we selected data that were easily
collected and predeﬁned in order to decrease that risk. Only two
physicians collected data from the medical charts to improve
consistency. Selecting children with the criterion ‘hospitalization’
could lead to recruitment bias. In fact some childrenwere probably
hospitalized because of their underlying medical conditions that
made them at risk of inﬂuenza complications. However the great
majority of diagnoses were related to clinical presentation
(pneumonia, asthma exacerbation, or neurological disorders such
as seizure or encephalitis-like symptoms). Among the children
admitted to the ICU, where the bias of being hospitalized for an
underlying condition is less, we noted that 14 of the 22 (64%) had
underlying conditions, similar to the whole cohort. There is a
certain subjectivity and variability in criteria for ICU admission,
therefore our experiencemay not be reproducible in other settings.
On the other hand, criteria for mechanical ventilation and non-
invasive respiratory support are more objective. Among the 14
children requiring respiratory support, 11 had underlying medical
conditions. The exact denominator of cases (total number of
children infected byH1N1)was unknown. Consequently the rate of
hospitalization related to inﬂuenza in children could not be
evaluated, but we were able to analyze all children hospitalized in
our institution. Excluding the 11 children forwhomhospitalization
was not related to novel inﬂuenza A (H1N1) helped to improve the
accuracy of the description of severe features of inﬂuenza
infection.
In conclusion, children hospitalized during the two successive
waves of H1N1 in our tertiary-care center weremainly school-aged
and had underlying medical conditions. Medical behavior changed
between the two waves probably because of a better knowledge of
the disease resulting in a reduction of 1 day in the duration of
hospitalization. This highlights the necessity of studying and
disseminatingclinicaldescriptionsofemergingdiseases to inﬂuence
clinicians in their management. In future pandemics, immunization
campaigns shouldbe initiatedpromptlyandaprioritizedpopulation
should be targeted based on clinical observation of the most
commonly hospitalized group, in this case school-aged children and
children with predisposing medical conditions.
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